West Pharmaceutical Services (WST) › Analysis

West Pharmaceutical Services (WST) stock analysis, November 3, 2026: Earnings-driven uptrend intact, stock sits near 52-week high

Published November 3, 2026 · WST chart, levels and live analysis

West Pharmaceutical Services (WST) raised its 2026 guidance on October 29, 2026 after third-quarter adjusted EPS of $2.66 beat expectations, and the shares have stayed near a 52-week high since. At $413.07, the stock sits 0.9% below its October 29 closing peak of $416.67. The balance of evidence for the next two to six weeks leans positive, with high conviction. The reward-to-risk from a breakout is thin, however.

Why it matters

The quarter was strong on every line that matters. Net sales were $874.5 million, up 8.7% and 11.9% organically, and adjusted EPS rose 35.7% to $2.66, according to the PR Newswire release. High-value product components, the engine of the story, grew 20% organically, and management lifted full-year guidance to $3.41–$3.42 billion in revenue and $9.38–$9.48 in adjusted EPS, as Seeking Alpha reported. The company also bought back $231 million of stock in the quarter and raised its quarterly dividend. The 10-Q shows net income of $214.0 million, up 53%.

The market had already been leaning this way, which explains the shape of the reaction. The stock is up 13.2% over the past month and 50.1% since the start of the year, so buyers were positioned before the numbers came out. The results confirmed that positioning rather than starting something new: the closing peak came on the day of the report, and shares have eased only slightly since. Volume today is 5.3% below its 20-day average, so the latest push has not drawn fresh heavy participation.

Over the past five days the stock gained 3.7%, while the S&P 500 (SPY) fell 2.1% and the healthcare sector ETF (XLV) rose 2.8%. Most of WST's move therefore came with its sector, and the market was a drag rather than a help. The stock's own contribution was about 0.9 points above XLV. That is a modest edge, but it extends a longer pattern: over 50 days WST leads the S&P 500 by 13.6 points and XLV by 4.6 points.

The argument about WST is whether this is a GLP-1 story or something broader. CNBC takes the broader side, arguing the quarter shows the company is more than a GLP-1 play, and cites a figure of $438.27. The cautious side does not appear in the news feed, but it shows in the numbers: the stock has run a long way, RSI is 82 and so deeply overbought, and the lowest of 15 analyst price targets, $340, is well below today's price. On valuation, the consensus is strong buy with a mean target of $471, 12.3% above the current price, and targets range from $340 to $500. The spread shows how far opinion differs on what a stock growing this way deserves to be worth.

What the evidence says

The long-term thesis is intact. Price is above both its 10-week and 40-week averages, the 50-day average at $369.89 sits well above the 200-day at $314.79, and the stock is 78.9% above its 52-week low of $230.95. This is a mature, extended uptrend that earnings have just reinforced, not a recovery or a turn.

For the next two to six weeks the balance of evidence leans positive, with high conviction: three of four points. The daily trend runs with the weekly uptrend, and the stock is leading both the S&P 500 and its sector over 50 days. Fundamentals have just moved in the same direction, with guidance raised and the highest-growth product line accelerating. Three of four points is strong but not complete, so the reading is not unqualified.

The strongest case against is stretch. An RSI of 82 means the stock is overbought, volume is running below average as price presses on the 52-week high, and the price is only 0.9% under that high, with limited room before the next obstacles at $425 and $450. Overbought conditions can persist in strong trends, and the trend and relative strength both point the same way. That is why the evidence still leans positive, and the stretch is a reason conviction is not higher.

Levels that matter

The structure holds above $400, a round number that is also the first level where a pullback would crack the pattern. Below it, the next support zones are $383.29 and $375. The trend itself would end below the 50-day average at $369.89, the level the assessment treats as the line between a pullback inside an uptrend and a change in the trend.

The breakout level is a daily close above $416.67, the 52-week high, on volume above its 20-day average. From there the first target is $425 and the second is $450. The breakout would be wrong below $397.42, which is $400 minus a quarter of the 14-day ATR. Against that stop, $425 offers 0.4 to 1 and $450 offers 1.7 to 1. The math does not reach the 3 to 1 that makes a breakout worth the risk. It would need a target well beyond $450 or a stop much closer to the entry, and neither is on the current map.

What would change the picture

The rule is a weekly close below $369.89, the 50-day average. That would mean the stock has given up the whole post-earnings advance and the intermediate trend is in question. The non-price fact that would do it is a slowdown in high-value product components, which grew 20% organically in the third quarter. If that growth fell back from the double-digit pace management guided to, or if guidance were cut, the premise behind the CNBC argument would weaken, and the move would likely follow.

What to watch

Get a message when the WST picture changes — the agent team watches the levels and the news for you.Create a free account

More WST analyses

Research & education, not advice. MarketCrew is AI-powered and can make mistakes.